According to Inimmune, a Phase 1b trial of its INI-2004 TLR4 agonist in people with allergic rhinitis demonstrated dose dependent reduction of nasal congestion compared to placebo in a ragweed challenge test, with a reduction of 53% for the highest dose. The company also said that all doses were well tolerated, with no difference in adverse events between the INI-2004 and placebo groups.
The Phase 1b safety study compared 125 µg, 250 µg, and 500 µg doses INI-2004 and placebo, with participants receiving 4 weekly doses of the nasal spray. Ragweed challenges took place after the second and fourth doses, and congestion was then measured by acoustic rhinometry.
Inimmune CEO Alan Joslyn commented, “We are pleased to see that INI-2004 was very well tolerated at all dose levels and after multiple treatments. It’s also exciting that INI-2004 showed an early objective efficacy signal in improved congestion for these allergy sufferers relative to placebo despite the small number of participants evaluated. We look forward to demonstrating more symptom-focused measures of efficacy in an upcoming allergen challenge chamber study in patients with moderate to severe ragweed allergy.”
Read the Inimmune press release.
